Adaptive Biotechnologies Corporation (ADPT) is a leading biotechnology business based in the US. It opened the day at $66.71 after a previous close of $67.01. During the day the price has varied from a low of $65.805 to a high of $68.13. The latest price was $67.74 (25 minute delay). Adaptive Biotechnologies is listed on the NYSE and employs 453 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, Adaptive Biotechnologies's share price has had significant positive movement.
Its last market close was $67.74, which is 49.57% up on its pre-crash value of $34.16 and 345.95% up on the lowest point reached during the March crash when the shares fell as low as $15.19.
If you had bought $1,000 worth of Adaptive Biotechnologies shares at the start of February 2020, those shares would have been worth $755.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,257.77.
|52-week range||$15.19 - $71.25|
|50-day moving average||$59.807|
|200-day moving average||$48.3672|
|Wall St. target price||$62.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.344|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-15)||4.07%|
|1 month (2020-12-24)||8.33%|
|3 months (2020-10-23)||36.85%|
|6 months (2020-07-24)||86.46%|
|1 year (2020-01-24)||121.73%|
Valuing Adaptive Biotechnologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptive Biotechnologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adaptive Biotechnologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 44x. In other words, Adaptive Biotechnologies shares trade at around 44x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||$92.4 million|
|Gross profit TTM||$-7,908,000|
|Return on assets TTM||-8.25%|
|Return on equity TTM||-17.97%|
|Market capitalisation||$9.3 billion|
TTM: trailing 12 months
There are currently 3.9 million Adaptive Biotechnologies shares held short by investors – that's known as Adaptive Biotechnologies's "short interest". This figure is 46.1% down from 7.2 million last month.
There are a few different ways that this level of interest in shorting Adaptive Biotechnologies shares can be evaluated.
Adaptive Biotechnologies's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies shares currently shorted divided by the average quantity of Adaptive Biotechnologies shares traded daily (recently around 817396.19450317). Adaptive Biotechnologies's SIR currently stands at 4.73. In other words for every 100,000 Adaptive Biotechnologies shares traded daily on the market, roughly 4730 shares are currently held short.
However Adaptive Biotechnologies's short interest can also be evaluated against the total number of Adaptive Biotechnologies shares, or, against the total number of tradable Adaptive Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adaptive Biotechnologies shares in existence, roughly 30 shares are currently held short) or 0.0569% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies shares, roughly 57 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies.
Find out more about how you can short Adaptive Biotechnologies stock.
We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.